LR
LRMR.US Larimar Therapeutics Inc
- Market cap
- USD 314M
- P/E
- -
- P/B
- 2.45x
- ROE
- -98.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LRMR.US undervalued?
Graham numberThe Graham number of Larimar Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Larimar Therapeutics Inc fundamental analysis
No fundamental analysis for Larimar Therapeutics Inc yet.
Larimar Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Full company profileLarimar Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Larimar Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -212K | -188K | -261K | -78.0K | -155K | -326K | -272K | -311K | -318K | -350K | - |
| Operating Income | -57.1M | -53.9M | -62.7M | -23.2M | -42.8M | -50.5M | -36.5M | -41.8M | -90.9M | -172M | -131M |
| EBITDA | -57.4M | -52.6M | -60.8M | -23.1M | -42.6M | -50.1M | -36.2M | -36.6M | -80.3M | -165M | -125M |
| Net Income | -57.9M | -52.0M | -61.4M | -23.1M | -42.3M | -50.3M | -34.2M | -36.9M | -80.6M | -166M | -125M |
| EPS | -25 | -23 | -23 | -7.43 | -3.56 | -2.93 | -1.33 | -0.84 | -1.32 | -2.27 | -1.20 |
| Balance Sheet | |||||||||||
| Total Assets | 132M | 106M | 122M | 5.20M | 105M | 78.7M | 126M | 95.9M | 200M | 146M | 165M |
| Total Liabilities | 9.89M | 27.3M | 28.5M | 5.90M | 15.0M | 14.3M | 15.5M | 14.2M | 28.4M | 67.8M | 37.9M |
| Shareholders' Equity | 122M | 78.2M | 93.3M | -694K | 89.7M | 64.4M | 111M | 81.7M | 172M | 78.1M | 127M |
| Cash & Short-term Investments | 129M | 102M | 118M | 1.01M | 92.6M | 70.1M | 118M | 86.8M | 183M | 137M | 156M |
| Total Debt | 3.59M | 20.0M | 20.6M | 8.56M | 6.52M | 6.00M | 5.41M | 5.55M | 5.12M | 4.07M | 4.96M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -52.0M | -43.8M | -51.5M | -22.7M | -42.2M | -42.1M | -27.6M | -33.5M | -70.8M | -113M | -177M |
| Capital Expenditure | 660K | 55.0K | 108K | 83.0K | 62.0K | 333K | 100K | 164K | 515K | 91.0K | 260K |
| Free Cash Flow | -52.6M | -43.8M | -51.6M | -22.8M | -42.3M | -42.4M | -27.7M | -33.6M | -71.3M | -113M | -178M |
| Ratios | |||||||||||
| ROE | -47.5% | -66.5% | -65.8% | - | -47.2% | -78.1% | -30.8% | -45.2% | -46.9% | -212.2% | -98.0% |
| ROA | -44.0% | -49.3% | -50.4% | -444.8% | -40.4% | -64.0% | -27.0% | -38.5% | -40.3% | -113.6% | -75.5% |
| Debt to Equity | 0.03x | 0.26x | 0.22x | - | 0.07x | 0.09x | 0.05x | 0.07x | 0.03x | 0.05x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Larimar Therapeutics Inc dividends
Larimar Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on May 29, 2020.
Who owns Larimar Therapeutics Inc
- Insiders 1.47%
- Institutions 95.04%
- Public & others 3.49%
- Shares outstanding 104M
- Free float 57.8M
Top funds holding LRMR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.21M | 2.12% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.69M | 1.62% | 0.00% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1.01M | 0.97% | +0.27% | Oct 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 849K | 0.82% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 748K | 0.72% | +2.96% | Aug 2026 |
| Vanguard Explorer Inv | 659K | 0.63% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 632K | 0.61% | -0.38% | Oct 2026 |
| MEDICAL BioHealth EUR Acc | 522K | 0.50% | +0.02% | Aug 2026 |
| Vanguard Russell 2000 ETF | 388K | 0.37% | +1.30% | Sep 2026 |
| iShares Biotechnology ETF | 375K | 0.36% | -0.19% | Oct 2026 |
| Driehaus Micro Cap Growth USD | 344K | 0.33% | +1.42% | Sep 2026 |
| Dimensional US Small Cap ETF | 341K | 0.33% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 286K | 0.28% | -6.75% | Sep 2026 |
| iShares Micro-Cap ETF | 200K | 0.19% | 0.00% | Oct 2026 |
| JPMorgan Small Cap Value I | 175K | 0.17% | -2.06% | Sep 2026 |
| Vanguard Health Care ETF | 174K | 0.17% | +0.11% | Sep 2026 |
| DFA US Micro Cap I | 171K | 0.16% | +4.83% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 165K | 0.16% | +165.73% | Aug 2026 |
| Adara Smaller Companies | 164K | 0.16% | -0.38% | Sep 2026 |
| Schwab Small Cap Index | 162K | 0.16% | 0.00% | Sep 2026 |
Top institutions holding LRMR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Deerfield Management Co | 35.6M | 34.28% | 0.00% | Jun 2026 |
| Blue Owl Capital Holdings LP | 9.16M | 8.82% | +28.70% | Jun 2026 |
| BlackRock Inc | 5.68M | 5.47% | +51.33% | Jun 2026 |
| Defilade Capital Management, L.P. | 3.67M | 3.53% | 0.00% | Jun 2026 |
| Driehaus Capital Management LLC | 3.16M | 3.05% | +7.80% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.97M | 2.86% | +3.79% | Jun 2026 |
| RTW INVESTMENTS, LLC | 2.57M | 2.47% | +71.07% | Jun 2026 |
| AQR Capital Management LLC | 2.37M | 2.28% | +190.08% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 2.01M | 1.94% | +115.59% | Jun 2026 |
| Dafna Capital Management LLC | 2.01M | 1.93% | -1.03% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.75M | 1.69% | +12.25% | Jun 2026 |
| Geode Capital Management, LLC | 1.68M | 1.62% | +51.43% | Jun 2026 |
| Qube Research & Technologies | 1.64M | 1.58% | +93.60% | Jun 2026 |
| Citadel Advisors Llc | 1.46M | 1.40% | +180.63% | Jun 2026 |
| State Street Corp | 1.41M | 1.36% | +54.92% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.40M | 1.35% | +245.13% | Jun 2026 |
| Woodline Partners LP | 1.40M | 1.35% | 0.00% | Jun 2026 |
| Millennium Management LLC | 1.33M | 1.28% | -63.23% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.13M | 1.09% | +17.54% | Sep 2026 |
| FMR Inc | 937K | 0.90% | +1,374.54% | Jun 2026 |
Larimar Therapeutics Inc company profile
- Company name
- Larimar Therapeutics Inc
- Ticker
- LRMR.US
- Exchange
- USA Stocks
- Listed since
- Jun 19, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 71
- Fiscal year end
- December
- Address
- Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004
- Phone
- 844 511 9056
- Website
- larimartx.com
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics Inc management
8- Dr. Carole S. Ben-Maimon M.D.CEO & Director · born 1959
- Mr. Michael Celano CPASecretary & CFO · born 1959
- Dr. Gopi Shankar M.B.A., Ph.D.Chief Development Officer · born 1971
- Mr. John B. Harlow Jr.President & COO · born 1976
- Mr. John BermanVice President of Finance & Administration
- Ms. Jennifer Spokes JohanssonVice President of Legal & Compliance
- Dr. Russell G. Clayton Sr., D.O.Chief Medical Officer · born 1961
- Mr. Francis Michael Conway CPAVP & Controller